ClinicalTrials.gg
Not yet recruitingNCT07951476Updated Nov 20, 2026

Comparing Itraconazole Alone With Itraconazole Plus Terbinafine for Adults With Resistant Tinea Corporis

A Phase 2 interventional study of itraconazole and Itraconazole + terbinafine in Tinea Corporis and Resistant Dermatophyte Infection, sponsored by Sheikh Zayed Medical College. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Sheikh Zayed Medical College · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This randomized controlled study will compare the effectiveness of oral itraconazole alone with a combination of oral itraconazole and terbinafine in adults with resistant tinea corporis (ringworm of the body). Resistant tinea corporis is a fungal skin infection that persists despite appropriate topical antifungal treatment or returns shortly after treatment.

Eligible patients aged 18-60 years with resistant tinea corporis confirmed by potassium hydroxide (KOH) microscopy will be randomly assigned to receive either oral itraconazole alone or oral itraconazole combined with terbinafine. Treatment response will be assessed clinically and by KOH microscopy.

The main purpose of the study is to determine whether the combination of itraconazole and terbinafine is more effective than itraconazole alone in achieving complete clinical and mycological cure after eight weeks of treatment. Patients who achieve treatment success will also be followed for a further four weeks to assess whether the infection returns.

The study hypothesis is that there is a difference in treatment efficacy between combined itraconazole with terbinafine and itraconazole alone in patients with resistant tinea corporis.

Read the detailed description

This is a randomized controlled trial designed to compare the efficacy of combined oral itraconazole and terbinafine with oral itraconazole alone in patients with resistant tinea corporis.

Tinea corporis is a superficial dermatophyte infection affecting glabrous skin. In this study, it includes infection involving the trunk, neck, upper limbs, or lower limbs, while infections involving the scalp, beard area, palms, soles, nails, and groin are excluded. Clinically, the infection is characterized by annular or polycyclic erythematous scaly plaques with an active raised margin, with or without central clearing and pruritus. The diagnosis will be confirmed by direct microscopy of skin scrapings obtained from the active scaly border. KOH microscopy will be considered positive when branching septate hyphae or arthroconidia are identified.

For the purpose of this study, resistant tinea corporis is defined as clinically diagnosed and KOH-positive infection that persists after at least four weeks of appropriate topical antifungal therapy or recurs within four weeks after apparent clearance.

Patients aged 18-60 years who meet the eligibility criteria will be enrolled after written informed consent. Eligible participants will be randomly allocated by lottery method into two treatment groups. Group A will receive oral itraconazole 100 mg twice daily after meals, while Group B will receive oral itraconazole 100 mg twice daily after meals together with oral terbinafine 250 mg once daily. Treatment will be administered for four weeks according to the study methodology.

Participants will be instructed to avoid topical corticosteroids, steroid-antifungal combination creams, over-the-counter antifungal treatment, and additional systemic antifungal therapy during the study period. Treatment compliance and adverse effects will be monitored. Adverse effects assessed during follow-up will include gastrointestinal symptoms, headache, rash, altered taste, jaundice, dark urine, fatigue, and other drug-related complaints. Liver function tests will be repeated every two weeks or earlier if clinically indicated.

At eight weeks from the start of treatment, participants will undergo clinical and mycological assessment. Complete clinical clearance will require disappearance of erythema, scaling, active raised border, new lesion formation, and pruritus. Mycological cure will be assessed by KOH microscopy of skin scrapings from the previously affected area or margin of any residual lesion.

Treatment efficacy will be defined as achievement of both complete clinical clearance and mycological cure at eight weeks. Participants who achieve treatment efficacy will be followed for an additional four weeks. At 12 weeks from the start of treatment, relapse will be assessed clinically and confirmed by KOH microscopy in participants with recurrent or new lesions suggestive of tinea corporis.

The study will be conducted in the Department of Dermatology, Sheikh Zayed Hospital, Rahim Yar Khan. The study duration will be six months after approval of the synopsis.

02

Conditions studied

  • Tinea Corporis
  • Resistant Dermatophyte Infection

Browse trials for

Keywords

  • Resistant Tinea Corporis
  • Tinea Corporis
  • Dermatophytosis
  • Recalcitrant Dermatophytosis
  • Itraconazole
  • Terbinafine
  • Combined Itraconazole and Terbinafine
  • Oral Antifungal Therapy
  • Treatment Efficacy
  • Complete Clinical Clearance
  • Randomized Controlled Trial
  • Relapse
03

In context

Tinea

41 studies on the registry are indexed under Tinea; 11 are open to participants now.

This study's planned enrollment of 104 is above the median of 75 across 35 interventional studies indexed under Tinea.

Browse Tinea studies →

Lead sponsor

Sheikh Zayed Medical College is the lead sponsor of 28 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Patients aged 18 to 60 years of either gender.

    2.Patients having tinea corporis involving glabrous skin of the trunk, neck, upper limbs or lower limbs as per operational definition.

    3.Patients fulfilling the definition of resistant tinea corporis as per operational definition.

    4.Patients willing to avoid topical , steroid-antifungal combinations, self-medication and any additional antifungal treatment during the study period.

Exclusion criteria

Exclusion Criteria:

  • 1. Patients who have used systemic antifungal therapy within two weeks before enrolment.

    2.Patients who have used topical or steroid-antifungal combination creams over the affected area within one week before enrolment.

    3.Pregnant or lactating women.

    4.Patients with known or previous serious adverse reaction to itraconazole, terbinafine or any related antifungal drug.

    5.Patients with known chronic liver disease, active hepatitis, jaundice, or baseline or aspartate aminotransferase more than two times the .

    6.Patients with congestive cardiac failure, history of ventricular dysfunction, or any cardiac condition in which itraconazole use is .

    7.Patients receiving drugs with important interaction risk with itraconazole or terbinafine, including drugs strongly dependent on cytochrome P450 metabolism, antiarrhythmics, certain statins, anticoagulants, anticonvulsants, rifampicin or other interacting medicines.

    8.Patients with known status, including infection, organ transplant, hematological , or active malignancy receiving treatment.

    9.Patients with uncontrolled diabetes mellitus ( > 8%).

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Active comparator
    Group A: Itraconazole Alone

    Group A will receive oral itraconazole 100 mg twice daily after meals for 8 weeks.

    Drug: itraconazole

  • Experimental
    Group B: Combined Itraconazole with Terbinafine

    Group B will receive oral itraconazole 100 mg twice daily after meals along with oral terbinafine 250 mg once daily for 8 weeks.

    Drug: Itraconazole + terbinafine

Interventions

  • out of total 104 patients, 52 patients will receive oral itraconazole 100 mg twice daily after meals for 8 weeks. Patients will receive itraconazole alone as systemic antifungal treatment for resistant tinea corporis.

  • DrugItraconazole + terbinafine

    Drug pages: ItraconazoleStudies of ItraconazoleItraconazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TerbinafineStudies of TerbinafineTerbinafine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    out of 104 patients, 52 patients will receive oral itraconazole 100 mg twice daily after meals along with oral terbinafine 250 mg once daily for 8 weeks for the treatment of resistant tinea corporis.

06

What researchers measure

Primary outcomes

  1. Treatment Efficacy at 8 Weeks

    The proportion of patients achieving treatment efficacy at the end of 8 weeks of treatment. Treatment efficacy will be assessed by the achievement of both complete clinical clearance and mycological cure. Complete clinical clearance will be defined as the disappearance of erythema, scaling, active raised border, new lesion formation and pruritus. Mycological cure will be confirmed by negative potassium hydroxide (KOH) microscopy.

    Time frame: 8 weeks after initiation of treatment.

Secondary outcomes

  1. Complete Clinical Clearance at 8 Weeks

    The proportion of patients achieving complete clinical clearance at the end of 8 weeks of treatment. Complete clinical clearance will be defined as complete disappearance of erythema, scaling, active raised border, new lesion formation and pruritus on clinical examination performed by the consultant dermatologist.

    Time frame: At 8 weeks after initiation of treatment

  2. Mycological Cure at 8 Weeks

    The proportion of patients achieving mycological cure at the end of 8 weeks of treatment. Mycological cure will be defined as negative potassium hydroxide (KOH) microscopy of skin scrapings taken from the previously affected lesion site or from the margin of any residual lesion. No branching septate hyphae or arthroconidia will be observed on direct microscopic examination.

    Time frame: At 8 weeks after initiation of treatment

  3. Relapse Rate at 12 Weeks

    The proportion of patients experiencing relapse after initial treatment success. Relapse will be assessed four weeks after completion of treatment (12 weeks from the start of treatment) and will be confirmed by the reappearance of clinically suggestive annular erythematous scaly lesions with active margins along with positive potassium hydroxide (KOH) microscopy. Relapse will only be assessed in patients who achieved treatment efficacy at 8 weeks.

    Time frame: 12 weeks after initiation of treatment.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Khurana A, Sharath S, Sardana K, Chowdhary A, Panesar S. Therapeutic Updates on the Management of Tinea Corporis or Cruris in the Era of Trichophyton Indotineae: Separating Evidence from Hype-A Narrative Review. Indian J Dermatol. 2023 Sep-Oct;68(5):525-540. doi: 10.4103/ijd.ijd_832_23. PubMed 38099117 ↗
  • Gupta AK, Wang T, Mann A, Polla Ravi S, Talukder M, Lincoln SA, Foreman HC, Kaplan B, Galili E, Piguet V, Shemer A, Bakotic WL. Antifungal resistance in dermatophytes - review of the epidemiology, diagnostic challenges and treatment strategies for managing Trichophyton indotineae infections. Expert Rev Anti Infect Ther. 2024 Sep;22(9):739-751. doi: 10.1080/14787210.2024.2390629. Epub 2024 Aug 18. PubMed 39114868 ↗
  • Khan SS, Hay R, Saunte DML. An international survey of recalcitrant and recurrent tinea of the glabrous skin-A potential indicator of antifungal resistance. J Eur Acad Dermatol Venereol. 2025 Jun;39(6):1185-1191. doi: 10.1111/jdv.20146. Epub 2024 Jul 13. PubMed 39001674 ↗
  • Shah SR, Vyas HR, Shah BJ, Jangid NC, Choudhary A, Gehlawat T, Mistry D, Joshi R. A Clinical-Mycological Study of Dermatophytosis in Western India with Focus on Antifungal Drug Resistance as a Factor in Recalcitrance. Indian J Dermatol. 2023 Mar-Apr;68(2):234. doi: 10.4103/ijd.ijd_999_22. PubMed 37275803 ↗
  • Chanyachailert P, Leeyaphan C, Bunyaratavej S. Cutaneous Fungal Infections Caused by Dermatophytes and Non-Dermatophytes: An Updated Comprehensive Review of Epidemiology, Clinical Presentations, and Diagnostic Testing. J Fungi (Basel). 2023 Jun 14;9(6):669. doi: 10.3390/jof9060669. PubMed 37367605 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers. Participant confidentiality and privacy will be maintained, and collected data will be used solely for the purposes of this research study

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 2026
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951476
Lead sponsor
Sheikh Zayed Medical College
Responsible party
Anum Mushtaq Khan (Postgraduate Resident Dermatology, Sheikh Zayed Medical College) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itraconazole · Terbinafine

Start the discussion